Key result
The ratio of factor VII clotting activity to amidolytic activity (VIIc/VIIam) serves as a measure of VII activation, with significantly decreased ratios observed in warfarin-treated patients.
Why the study?
Does a coupled amidolytic assay for factor VII correlate with a clotting assay and enable detection of activated factor VII in various patient populations?
Observational (n=100)
Does a coupled amidolytic assay for factor VII correlate with a clotting assay and enable detection of activated factor VII in various patient populations?
Answers are grounded in this paper and cite their sources.
The development of a coupled amidolytic assay for factor VII allows for the calculation of a VIIc/VIIam ratio, providing a novel method to evaluate the activity state of factor VII in thrombotic disorders.
A coupled amidolytic assay for factor VII (VII) has been developed that when used with a clotting assay for VII enables detection of activated VII. In the assay, VII in a test material determines generation of factor Xa in a mixture of purified factor X, tissue factor, and calcium; factor Xa is measured with a chromogenic substrate. Factor VII activity in the coupled amidolytic assay (VIIam) correlated well with VII activity in a one-stage clotting assay (VIIc) in 57 healthy subjects, 5 patients with hereditary VII deficiency, and 11 patients with liver disease. Activation of plasma VII by kaolin, clotting, or cold strikingly increased VIIc but not VIIam levels. Thus the ratio VIIc/VIIam (VII activity ratio) is a measure of VII activation. In 27 warfarin-treated patients the mean VII activity ratio was significantly decreased, reflecting a greater decline in VIIc than in VIIam. This probably stems from partially carboxylated VII being able to act during the 3-min incubation of the amidolytic assay but unable to act rapidly enough to affect the clotting assay. Measurement of VIIc/VIIam should enable evaluation of the activity state of VII in thrombotic disorders and in components for transfusion therapy.
No takes yet. Share an insight, caveat, or question.
Seligsohn et al. (1978) conducted an observational in Healthy subjects, hereditary VII deficiency, liver disease, and warfarin therapy (n=100). Coupled amidolytic assay for factor VII (VIIam) vs. One-stage clotting assay (VIIc) was evaluated on Factor VII activity ratio (VIIc/VIIam). The ratio of factor VII clotting activity to amidolytic activity (VIIc/VIIam) serves as a measure of VII activation, with significantly decreased ratios observed in warfarin-treated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: